Anti-SARS-CoV-2 Neutralizing sdAb (VHH-Human IgG Fc) (CAT#: VAb-065SX)

• Product Overview
• Recombinant Llama VHH-Human IgG Fc for studying neutralization of SARS-CoV-2 and detection of SARS-CoV-2 Spike Protein. Neutralizing activity validated for SARS-CoV-2 wild type Spike protein RBD.

• Target
• SARS-CoV-2

• Clonality
• VHH

• Isotype
• Llama VHH-Human IgG Fc

• Concertration
• 1 mg/ml

• Specificity
• SARS-CoV-2 wild type Spike protein RBD

• Type
• Antibody

• Conjugate
• Unconjugated

• Form
• Liquid

• Buffer Solution
• PBS, pH 7.4, 3% sucrose.

• Applications
• Used for WB, ELISA, IHC-P, FCM, ICC/IF, IP.

• Storage
• Store at 2°C to 8°C short term, -20°C long term.

• Introduction
• The 2019 novel coronavirus, or "SARS-CoV-2", was discovered because of Wuhan virus pneumonia cases in 2019, and was named by the World Health Organization on January 12, 2020. It belongs to the beta genera of the Coronaviridae family, together with SARS coronavirus in 2003 and MERS coronavirus in 2012. The alignment between SARS-CoV-2 and 2003 SARS CoV has about 70% sequence similarity and 40% sequence similarity with MERS CoV. The coronavirus genome encodes a spike protein, an envelope protein, a membrane protein, and a nucleoprotein. Among them, spike protein is the most important surface membrane protein of coronavirus.

• Alternative Names
• 2019 novel coronavirus; SARS-CoV-2; Coronaviridae